Key Highlights

  • UCB’s Bimzelx (bimekizumab) beat AbbVie’s Skyrizi (risankizumab) in a head-to-head psoriatic-arthritis trial, with 49% versus 38% of patients achieving reduced disease activity
  • Belgian drugmaker UCB claims Bimzelx is now “unde­feated” in three major psoriasis-related head-to-head studies against blockbusters
  • UCB’s shares reacted positively, climbing 2.56% to $33.30 amid the new data presentation
  • Analysts see the win as a strategic thrust against AbbVie’s $8bn-a-year Skyrizi Franchise in immunology
  • Psoriatic arthritis affects roughly 30% of the 125m psoriasis patients worldwide, a $15bn market opportunity

Bimzelx’s latest win reshapes the psoriasis market

UCB (Euronext Brussels: UCB) has deepened its claim on the psoriasis market after releasing detailed data from a head-to-head psoriatic-arthritis trial showing Bimzelx’s superiority over AbbVie’s (NYSE: ABBV) Skyrizi. In the study, 49% of patients treated with Bimzelx achieved a 75% reduction in disease-activity scores, compared with 38% on Skyrizi—results that analysts called “statistically significant and clinically meaningful.” The data, presented at a major rheumatology congress, reinforce Bimzelx’s growing reputation as a front-runner in interleukin-17 (IL-17) inhibition, a class that has already upended older Biologics.

Yet the victory is more than clinical bragging rights. Psoriatic arthritis—a painful, inflammatory joint condition—affects up to 30% of the 125m people globally living with psoriasis. The $15bn immunology market is fiercely contested; AbbVie’s Skyrizi alone generated $8.3bn in 2023, making it one of the industry’s fastest-growing Assets. By outperforming Skyrizi in direct comparison, Bimzelx not only chips away at Market Share but also questions the durability of AbbVie’s dominance in the IL-23 and IL-17 axes. “This is a clear signal that second-generation IL-17 inhibitors can outperform even the best-in-class first-generation agents,” said Leerink Partners analyst Puneet Souda.

The victory also underscores UCB’s focused strategy: after years of playing catch-up in psoriasis, the Belgian biotech is now leading in comparative trials. Bimzelx has now “strung together” three consecutive wins against major rivals—first versus Novartis’s Cosentyx, then against Lilly’s Taltz, and now against Skyrizi—cementing its status as the “unde­feated” challenger in inflammatory disease. “UCB is no longer the underdog,” noted Bernstein analyst Ronny Gal. “It’s writing the playbook.”

Investor sentiment lifts as UCB flexes clinical muscle

Financial markets reacted promptly to the news. UCB’s shares rose 2.56% to $33.30 on the day of the data release, paring losses from earlier in the year as investors reassessed the company’s pipeline prospects. The move follows a broader rebound in European biotech stocks, which have lagged behind U.S. peers amid regulatory scrutiny and pricing pressures. Yet UCB’s outperformance is more than cyclical; it reflects growing confidence that Bimzelx can carve out a durable position in a crowded field.

The company’s Market Capitalisation now stands at roughly $30bn, buoyed by expectations that Bimzelx could eventually rival—or surpass—Skyrizi in Revenue terms. While Bimzelx’s current label is limited to moderate-to-severe plaque psoriasis and psoriatic arthritis, UCB is pushing into ankylosing spondylitis and axial spondyloarthritis, two high-value indications with fewer branded Options. “The clinical edge demonstrated here gives UCB Leverage in payer negotiations,” said SVB Securities analyst David Risinger. “That’s worth several percentage points of market share.”

Still, the path forward is not without risk. Bimzelx’s safety profile—particularly its association with mild-to-moderate infections—remains a watchpoint for regulators and clinicians. Moreover, AbbVie is unlikely to cede ground easily; Skyrizi’s rapid uptake in dermatology and expanding label expansions in gastroenterology and rheumatology provide a buffer. “AbbVie’s commercial engine is formidable,” cautioned Credit Suisse analyst James Shin. “Price competition and rebate structures could blunt UCB’s clinical advantage.”

The psoriasis market braces for a three-way battle

The immunology market is evolving from a Duopoly—dominated historically by TNF inhibitors like Humira—into a more fragmented battleground. Three contenders now vie for supremacy in the IL-17 and IL-23 pathways: AbbVie’s Skyrizi, Lilly’s Taltz, and UCB’s Bimzelx. Each offers distinct mechanisms and dosing advantages; Skyrizi, for instance, requires quarterly injections, while Bimzelx is administered every four to eight weeks depending on formulation. Payers, increasingly cost-conscious, are beginning to favour agents with longer dosing intervals and deeper efficacy.

Yet the market’s expansion is tempered by biosimilar encroachment. Humira’s U.S. Patent cliff in 2023 unleashed a wave of Biosimilars, pressuring prices across the class. While Skyrizi and Bimzelx remain protected by composition-of-matter patents into the mid-2030s, the spectre of biosimilars looms. “The real prize isn’t just incremental share,” said UBS analyst Laura Sutcliffe. “It’s capturing the first-line prescription before biosimilars gain traction in the inflammatory space.”

The battle lines are also being drawn in the clinic. UCB is running additional head-to-head trials against Cosentyx and Taltz in ankylosing spondylitis, with results expected in late 2025. If Bimzelx can replicate its PsA success in axial disease, it could force a rethink of first-line treatment algorithms. Meanwhile, AbbVie is investing heavily in Skyrizi’s expansion into ulcerative colitis and Crohn’s disease, aiming to offset any dermatology losses. “The market is big enough for three winners,” observed Jefferies analyst Michael Yee. “But only if each can prove unique value.”

Regulatory and geopolitical tailwinds—or headwinds?

UCB’s clinical victory arrives at a politically sensitive moment for drug pricing. The European Commission is pushing for stricter HTA alignment, while the U.S. Inflation Reduction Act’s drug-price negotiation provisions threaten to erode margins for high-priced biologics. Yet Bimzelx’s early positioning in Europe—where UCB has deep payer relationships—could provide a buffer against U.S. pricing pressure. “UCB’s geographic footprint is an underappreciated asset,” said HSBC analyst Martin Austin. “It’s less exposed to U.S. Medicare negotiation than peers.”

Geopolitically, UCB’s Brussels headquarters insulates it from some of the Supply-chain disruptions plaguing U.S.-based rivals. The company’s Manufacturing footprint in Belgium and Germany ensures continuity of supply, a critical advantage in an era of active pharmaceutical ingredient shortages. However, the company is not immune to broader economic headwinds. A potential Recession in Europe could dampen hospital budgets and slow formulary adoption for premium-priced biologics.

Regulatory scrutiny remains intense. The EMA and FDA have both flagged safety signals around IL-17 inhibitors, particularly regarding candidal infections and inflammatory bowel disease exacerbations. UCB will need to monitor post-Marketing data closely as Bimzelx gains wider use. “The agency’s bar for new IL-17 agents is higher now,” noted ISI Evercore analyst Umer Raffat. “UCB will need to demonstrate not just efficacy, but long-term safety.”

What’s next for Bimzelx—and its rivals?

The next 12–18 months will be decisive for Bimzelx’s trajectory. UCB plans to file for an ankylosing spondylitis label expansion in 2025, a move that could unlock an additional $1bn–$1.5bn in peak sales, according to consensus estimates. Analysts also expect label expansions for axial spondyloarthritis and hidradenitis suppurativa, broadening Bimzelx’s addressable market to nearly $10bn by 2030.

For AbbVie, the imperative is clear: defend Skyrizi’s dominance in dermatology while accelerating into rheumatology. Lilly’s Taltz, meanwhile, is recalibrating its strategy after mixed trial results in PsA, focusing on earlier lines of therapy. “The psoriasis arms race is entering a new phase,” said William Blair analyst Matt Phipps. “The next six quarters will determine who leads—and who follows.”

Investors will watch closely for UCB’s next clinical salvo: the Phase III BE MOBILE-1 and BE MOBILE-2 trials in axial spondyloarthritis. Positive data could trigger a re-rating of UCB’s pipeline, justifying its premium valuation relative to peers. Yet the company must also navigate the perennial risks of immunology: payer resistance, safety surprises, and the spectre of biosimilars. “Bimzelx has momentum,” summed up Citi analyst Andrew Baum. “But the road to blockbuster status is paved with execution—and luck.”